Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K, dated February 13, 2026, reports a material definitive agreement entered into by Mainz Biomed N.V. (trading symbol: MYNZ). The filing details a private placement investment with David E. Lazar, the appointment of Mr. Lazar to the Board of Directors, and the execution of settlement agreements with certain officers and directors. The company is incorporated in The Netherlands and listed on the Nasdaq Capital Market.

Key Financial Metrics and Transaction Details

  • Investment Proceeds: The First Closing generated aggregate gross proceeds of $3 million from the sale of Series A, B, and C Preferred Shares at $1.00 per share.
  • Future Funding: The agreement contemplates a Final Closing for an additional $3 million gross proceeds from Series D and E Preferred Shares at $1.50 per share, subject to shareholder approval.
  • Capital Structure Impact: Upon full conversion, the Preferred Shares will represent approximately 95.6% of the company's issued and outstanding Ordinary Shares on a fully diluted basis.
  • Settlement Costs: The company agreed to make aggregate payments of approximately $1.9 million to two officers and three directors under Settlement Agreements, covering accrued salary, bonuses, healthcare, and severance.
  • Use of Proceeds: Net proceeds will be used for operations, general corporate purposes, working capital, and transaction expenses.

Material Changes and Governance

The filing discloses significant changes to the company's capital structure and governance:

  • Board Appointment: David E. Lazar was appointed as a temporary non-executive director and Chair of the Board effective February 13, 2026.
  • Shareholder Approval Requirement: Due to the potential issuance of shares exceeding 20% of outstanding stock and the potential change of control, the company must obtain shareholder approval (Conversion Approval) to allow full conversion of the Preferred Shares.
  • Shareholder Meeting: The company must hold an extraordinary shareholder meeting on or before April 15, 2026, to approve the conversion, the election of directors, and a potential reverse stock split (ratio between 1-for-2 and 1-for-99).
  • Voting Agreement: A voting agreement was executed with shareholders owning approximately 12.4% of outstanding shares to vote in favor of the investment proposals.

Guidance, Risks, and Contingencies

The transaction is subject to several contingencies and risks:

  • Conversion Limitation: Preferred Shares cannot be converted if it would cause Mr. Lazar to exceed a 19.99% beneficial ownership limitation prior to shareholder approval.
  • Failure to Obtain Approval: If shareholder approval is not obtained at the initial meeting or a subsequent meeting within 90 days, the company is obligated to issue up to 19.99% of outstanding Ordinary Shares to Mr. Lazar at a price equal to the closing stock price plus $0.02.
  • Trading Suspension: The Final Closing is contingent on no permanent or extended trading suspension of the company's Ordinary Shares.
  • Forward-Looking Statements: The filing includes standard disclaimers regarding risks that could cause actual results to differ materially from projections, including the completion of the Final Closing and the financial impact of the investment.

Investor Verification Checklist

  • Verify the outcome of the extraordinary shareholder meeting scheduled for or before April 15, 2026, regarding the Conversion Approval and reverse stock split.
  • Confirm the timing and conditions for the Final Closing and the receipt of the additional $3 million.
  • Review the specific terms of the reverse stock split ratio once determined by the Board.
  • Monitor the company's cash position and liquidity given the $1.9 million settlement obligation and the reliance on future funding.
  • Assess the impact of the potential 95.6% dilution on existing shareholders if the Preferred Shares are fully converted.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.